Abstract: OBJECTIVE: To investigate the relationship between the mutation patterns of rtM204V/I (methionine to valine or isoleucine at position rt204 of reverse transcriptase domain) in hepatitis B virus (HBV) polymerase gene and HBV genotypes.
Abstract: Luciferase assay showed that the rtM204I/V mutant HBs could activate the transcription of hfgl2 promoter compared with the wild type HBs.
Abstract: To investigate whether the nucleotide (nucleoside)-induced resistant mutations of HBs potentiate transcription of hfgl2 prothrombinase gene, we generated two mutant HB expression constructs harboring rtM204V/sI195M or rtM204I/sW196L mutations.
[Evolution of hepatitis B virus quasispecies during antiviral therapy in one chronic hepatitis B patient].
Introduction: with the most important occurring in the highly conserved tyrosine-methionine-asparate-aspartate (YMDD) motif, involving a change from methionine at position 204 in the reverse transcriptase domain (rt204) to either a valine or isoleucine residue (rtM204V/I) or, more rarely, a serine residue.
Result: A 10th patient was excluded because the patient's virus had the M204I mutation at the initiation of HAART and further investigation revealed that this patient had previously been on zidovudine AZT/3TC dual therapy when the mutation was likely to have emerged.
Frequency and mutation patterns of resistance in patients with chronic hepatitis B infection treated with nucleos(t)ide analogs in add-on and switch strategies.
Introduction: LdT selects for mutations in the YMDD motif, and to date, only rtM204I (but not rtM204V) has been observed .
Introduction: Moreover, studies conducted in Turkish patients having treated or untreated CHB infections indicated that HBV drug resistance is frequently mediated by rtM204V (YVDD variant) and rtM204I (YIDD variant) mutations, and rtM204S (YSDD variant) mutations with or without compensatory mutations such as rtV173L
Characterization of hepatitis B virus genotypes/subgenotypes in 1,301 patients with chronic hepatitis B in North China.
Abstract: HBV/C infection had a higher incidence of lamivudine-resistant mutations rtM204I/V (44.9% vs.
Monitoring of therapy in patients with chronic hepatitis B virus.
PMID: 19550344
2010
European journal of gastroenterology & hepatology
Abstract: In the viral response to treatment, three patients developed substitutions at rtM204I associated with LAM resistance and one of these patients presented rtM204V/I plus rtL180M mutation.
Abstract: With regard to this case, the same results were observed by INNO-LiPA HBV DR v3 and direct sequencing, but by direct sequencing we detected an extra mutation rtQ215S that was present in two patients: one patient who was on treatment with LAM had an rtQ215S mutation in addition to an rtM204I, and the second patient treated with ADV had
Dysregulation of hepatocyte cell cycle and cell viability by hepatitis B virus.
Abstract: Cell viability was reduced and cleaved caspase 3 levels were increased in HBV- and rtM204I-infected cells.
Abstract: METHODS: We have used a recombinant adeno-HBV model system to investigate the effect of infection with HBV and the replication defective lamivudine resistant mutant rtM204I mutant on hepatocyte cell cycle and cell viability.
Abstract: Perturbations in these cellular processes are likely to underlie HBV-associated liver oncogenic transformation and may help explain the ongoing risk of developing hepatocellular carcinoma in individuals in whom the lamivudine resistant rtM204I mutant emerges.
Abstract: rAdHBV-M204I-infected Huh7 cells also demonstrated
Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.
Abstract: Replication-competent HBV strains with sG145R or sP120T and LAM resistance (rtM204I or rtL180M/rtM204V) were generated on an HBeAg-positive and an HBeAg-negative background with precore (PC) and basal core promoter (BCP) mutants.
Mechanism of entecavir resistance of hepatitis B virus with viral breakthrough as determined by long-term clinical assessment and molecular docking simulation.
PMID: 19933798
2010
Antimicrobial agents and chemotherapy
Abstract: Multivariate logistic regression analysis adjusted for age, gender, HBV DNA levels, and LVD resistance (LVDr) (L180M and M204V, but not M204I) indicated that T184 substitutions and S202G (not S202C) were a significant factor for BT (adjusted odds ratio [OR], 141.12, and 95% confidence interval [CI], 6.94 to 2,870.20; OR, 201.25, and 95% CI, 11.22 to 3608.65, respectively).
HBV mutation literature information.
PMID: 
2011
Zhonghua gan zang bing za zhi
Browser Board
Co-occurred Entities
Filtrator
ViMRT